Literature DB >> 10479479

Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort.

B R Akerman1, H Lemass, L M Chow, D M Lambert, C Greenberg, C Bibeau, O A Mamer, E P Treacy.   

Abstract

Trimethylaminuria (TMAuria) (McKusick 602079) first described in 1970 is an autosomal recessive condition caused by a partial or total incapacity to catalyze the N-oxygenation of the odorous compound trimethylamine (TMA). The result is a severe body odor and associated psychosocial conditions. This inborn error of metabolism, previously thought to be rare, is now being increasingly detected in severe and milder presentations. Mutations of a phase 1 detoxicating gene, flavin-containing monooxygenase 3 (FMO3), have been shown to cause TMAuria. Herein we describe a cohort of individuals ascertained in North America with severe TMAuria, defined by a reduction of TMA oxidation below 50% of normal with genotype-phenotype correlations. We detected four new FMO3 mutations; two were missense (A52T and R387L), one was nonsense (E314X). The fourth allele is apparently composed of two relatively common polymorphisms (K158-G308) found in the general population. On the basis of this study we conclude that one common mutation and an increasing number of private mutations in individuals of different ethnic origins cause TMAuria in this cohort. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479479     DOI: 10.1006/mgme.1999.2885

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  15 in total

Review 1.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

2.  Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

Authors:  E Störmer; I Roots; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 3.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

4.  Trimethylaminuria: causes and diagnosis of a socially distressing condition.

Authors:  Richard J Mackay; Christopher J McEntyre; Caroline Henderson; Michael Lever; Peter M George
Journal:  Clin Biochem Rev       Date:  2011-02

5.  Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children.

Authors:  R A Chalmers; M D Bain; H Michelakakis; J Zschocke; R A Iles
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

6.  Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status.

Authors:  Robin M Voigt; Zeneng Wang; J Mark Brown; Phillip A Engen; Ankur Naqib; Christopher G Goetz; Deborah A Hall; Leo Verhagen Metman; Maliha Shaikh; Christopher B Forsyth; Ali Keshavarzian
Journal:  Neurobiol Dis       Date:  2022-05-30       Impact factor: 7.046

Review 7.  Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis.

Authors:  Rebecca C Schugar; J Mark Brown
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

8.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

9.  Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.

Authors:  Catherine K Yeung; Elinor T Adman; Allan E Rettie
Journal:  Arch Biochem Biophys       Date:  2007-05-02       Impact factor: 4.013

10.  Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians.

Authors:  Ciara Dolan; Denis C Shields; Alice Stanton; Eoin O'Brien; Deborah M Lambert; John K O'Brien; Eileen P Treacy
Journal:  BMC Med Genet       Date:  2005-12-02       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.